Neoadjuvant Therapy and Axillary Lymph Node Status in HER2-Positive Breast Cancer
Author:
Affiliation:
1. Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria
2. Department of Statistics, University of Innsbruck, Innsbruck, Austria
3. Department of Pathology, Medical University of Vienna, Vienna, Austria
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/07357907.2023.2238312
Reference20 articles.
1. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
2. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
4. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
5. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3